Official PayPal Seal

Portfolio Diversification Begins at Alexion; Shares Cheap

publication date: Apr 30, 2018
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Image Source: Alexion

We view the acquisition of differentiated, late-stage molecules at an attractive rate as the optimal use of free cash flow for many in the biotech industry. The finite commercial life of a patented drug forces continued innovation as near-total revenue erosion is a certainty once patent protection has lapsed. Let’s review some of the recent events at Alexion to gain a further understanding of the underlying trends affecting the business.

Subscribe Now to Gain Access!

This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!

Click to Learn More about Valuentum

If you are already a subscriber, please

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.

To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.